选择语言

Human HVEM (Luc) HEK293 Reporter Cell

用户评价
货号-规格
价格
Qty.
CHEK-ATF105-2Vials (1Vial X 2)
询价
合计0件 产品金额¥ 0

产品详情

    1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
    2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
    3. Comprehensive application data to support assay development and validation
    4. Full tracible record, stringent quality control and validated cell passage stability
    5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
    6. Global commercial license assistance whenever regulatory filing is required
  • 描述(Description)

    The Human HVEM (Luc) HEK293 Reporter Cell was engineered to not only express NF-kB signaling response element, but also express the receptor full length human HVEM (Gene ID: 8764). When co-cultured with target cells expressing human BTLA, the BTLA/HVEM interaction drives NF-kB-mediated luminescence. Blocking the BTLA/HVEM interaction by either anti-BTLA or anti-HVEM antibodies results in a decrease in luminescence.

  • 应用说明(Application)

    • Screen for anti-human BTLA antibody or anti-human HVEM antibody blocking BTLA/HVEM interaction.

    HVEM Assay Principles

  • 生长特性(Growth Properties)

    Adherent

  • 筛选标记(Selection Marker)

    Hygromycin B (20 μg/mL)

  • 培养基(Complete Growth Medium)

    DMEM medium + 10% FBS

  • 冻存液(Freeze Medium)

    Serum-free cell cryopreservation medium

  • 装量(Quantity)

    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

  • 存储(Storage)

    Frozen in liquid nitrogen.

  • 支原体检测(Mycoplasma Testing)

    Negative

  • 无菌检测(Sterility Testing)

    Negative

  • 使用说明(Instructions for Use)

    See data sheet for detailed culturing and assay protocol.

  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

数据展示

  • Receptor Assay

     HVEM FACS

    Expression analysis of human HVEM on Human HVEM (Luc) HEK293 Reporter Cell by FACS.
    Cell surface staining was performed on Human HVEM (Luc) HEK293 Reporter Cell or negative control cell using
    PE-labeled anti-human HVEM antibody

    Protocol
  • Application

     HVEM APPLICATION

    Inhibition of human BTLA overexpressing on CHO cells induced reporter activity by anti-human BTLA antibody.
    This reporter cell was incubated with serial dilutions of antibodies in the presence of CHO/Human BTLA Stable Cell Line. The EC50 of anti-human BTLA neutralizing antibody is approximately 0.212 μg/mL.

    Protocol
  • Signaling Bioassay

     HVEM SIGNALING

    Response to human BTLA (FOLD).
    This reporter cell was incubated with CHO/Human BTLA Stable Cell Line (Cat. No. SCCHO-ATP110) at four different cell densities. The human BTLA overexpressing on CHO cells can activate HVEM signaling with the max induction fold 103.69 at the density of 8x10^4 cells/well.

    Protocol
  • Passage Stability

     HVEM PASSAGE

    Passage stability analysis by Signaling Bioassay.
    The continuously growing Human HVEM (Luc) HEK293 Reporter Cell was incubated with CHO/Human BTLA Stable Cell Line (Cat. No. SCCHO-ATP110). The human BTLA overexpressing on CHO cells stimulated response demonstrates passage stabilization (fold induction) across passage 7-25.

    Protocol
*如有相关细胞池需求请联系我们

用户评价
发表评论

背景介绍

Herpesvirus entry mediator (HVEM) is also known as TNFRSF14, TR2 (TNF receptorlike molecule) and ATAR (another TRAF associated receptor), is a type I membrane protein belonging to the TNF/NGF receptor superfamily. HVEM expression has been detected in peripheral blood T cells, B cells, monocytes and in various tissues enriched in lymphoid cells. The extracellular domain of HVEM has been shown to interact directly with the herpes simplex virus envelope glycoprotein D (gD). Two TNF superfamily ligands, including the secreted TNFβ (lymphotoxin α) and the membrane protein LIGHT (lymphotoxins, exhibits inducible expression, and competes with HSV glycoprotein D for HVEM, a receptor expressed by T lymphocytes), have been shown to be the cellular ligands for HVEM. Besides HVEM, LIGHT can also interact with LTβR, the receptor for lymphotoxin αβ heterotrimer. The role of the HVEM LIGHT /LTβ receptor ligand pair in immune function and herpesvirus pathobiology remains to be elucidated.

重要声明

  • Limited Use&License Disclosure

    BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.

    1. If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
    2. Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
    3. This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use. You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
    4. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
    5. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
    6. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order.cn@acrobiosystems.com for further details.

前沿进展

 
药物研发进展
  • 英文全称:

    Tumor necrosis factor receptor superfamily member 14

  • 中文全称:

    肿瘤坏死因子受体超家族成员14

  • 种类:

  • 上市药物数量:

    0 详情

  • 临床药物数量:

    0 详情

  • 最高研发阶段:

    临床前

联系我们
项目合作
查看更多项目
  • 产品基础信息
  • 产品详情
  • 数据展示
  • 用户评价
  • 背景介绍
  • 重要声明